Acadia Pharmaceuticals reported that its phase 2 Alzheimer’s disease trial missed the primary endpoint. The company acknowledged the miss but said the overall results still point to potential benefit, leading it to conclude that moving into phase 3 is “absolutely worth” pursuing.
Analysts who follow the program appear to share that view. According to the source, both the company and analysts saw enough encouraging signals in the data to support continuing development, rather than halting the candidate. The agreement suggests the secondary or subgroup findings may carry more weight than the top-line miss.
No major disagreements between the company and analysts were noted in the source. The next step is a phase 3 program, though the source does not specify trial design, timing, or regulatory implications.